Allergy Asthma & Respiratory Disease is a pioneering journal dedicated to advancing research and clinical practice in the fields of allergy, asthma, and related respiratory diseases. Published by the esteemed Korean Academy of Asthma Allergy & Clinical Immunology, this journal aims to disseminate high-quality, peer-reviewed articles that contribute to the understanding, diagnosis, and treatment of these prevalent health issues. Although it operates under a subscription model, it maintains a robust reputation for being a pivotal resource in respiratory health, attracting authors and researchers worldwide. The journal emphasizes interdisciplinary approaches and encourages submissions that span from molecular biology to public health perspectives, making it a vital platform for professionals, researchers, and students eager to deepen their knowledge in respiratory medicine. With a commitment to fostering academic discourse in South Korea and beyond, Allergy Asthma & Respiratory Disease is positioned as a significant contributor to the global conversation on respiratory health.

ALLERGOLOGIA ET IMMUNOPATHOLOGIA is a distinguished academic journal dedicated to the field of immunology and allergy, published by CODON PUBLICATIONS, based in Singapore. With its ISSN 0301-0546 and E-ISSN 1578-1267, this journal aims to provide an open platform for researchers and practitioners to share their findings, emphasizing topics related to immunopathology and respiratory health. Covering a broad scope from 1973 to 2024, it currently holds a notable position in several category quartiles, including Q3 in Immunology and Allergy, and Q3 in Pulmonary and Respiratory Medicine as of 2023. Despite the absence of an open access option, the journal maintains an essential role in disseminating pivotal research, reflected in its Scopus rankings that position it within the core of its discipline. With an impact factor acknowledging the significance of its contributions, ALLERGOLOGIA ET IMMUNOPATHOLOGIA continues to be a vital resource for ongoing education and advancement in immunological and allergic research.

World Allergy Organization Journal is a premier open-access publication dedicated to advancing the understanding and treatment of allergic diseases and related conditions. Published by ELSEVIER, this journal boasts a commendable impact factor and ranks in the second quartile for both Immunology and Allergy, as well as the first quartile in Pulmonary and Respiratory Medicine. Since its inception as an open-access journal in 2008, it has consistently aimed to provide a credible platform for researchers, clinicians, and students to disseminate original research, reviews, and clinical studies. With its emphasis on high-quality scholarship and practical applications, the World Allergy Organization Journal plays a crucial role in bridging theoretical knowledge with clinical practice, making significant contributions to the fields of immunology, allergy, and respiratory medicine. The journal is particularly notable for its accessibility to a global audience, exemplified by its open-access model since 2008, promoting a wider exchange of ideas and innovations across borders.

Therapeutic Advances in Allergy and Rhinology, published by SAGE Publications Inc, is an esteemed journal that focuses on advancing the fields of allergy and rhinology through innovative and impactful research. As an Open Access journal, it provides a platform for researchers, clinicians, and students to share significant findings and therapeutic developments aimed at improving patient outcomes related to allergic conditions and nasal disorders. The journal aims to publish high-quality peer-reviewed articles, reviews, and case studies that contribute to a deeper understanding of the pathophysiology and management of allergies and rhinological conditions. By fostering collaborative dialogue across various disciplines, Therapeutic Advances in Allergy and Rhinology plays a crucial role in enhancing clinical practice and guiding future research in this vital area of health. With an ISSN of 2753-4030, the journal continues to establish itself as a key resource for anyone involved in allergy and rhinology research and practice.

Frontiers in Allergy is a pioneering open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing the frontiers of research in the fields of Immunology and Infectious Diseases. Launched in 2020 and based in Lausanne, Switzerland, this journal provides a dynamic platform for researchers, professionals, and students to share innovative findings and insights related to allergic disorders and their broader immunological implications. With a respectable Q2 ranking in both Immunology and Allergy and Infectious Diseases categories, as well as being indexed in Scopus, this journal is emerging as a significant resource for the scientific community. The open-access model ensures wide dissemination of valuable knowledge, facilitating collaboration and breakthroughs in treatments and understanding of allergies and related conditions. Frontiers in Allergy invites contributions that drive forward the understanding of immune responses, allergy prevention, and management, solidifying its role as a crucial player in the sustainability and growth of health sciences.

Allergy Asthma & Immunology Research, published by the Korean Academy of Asthma Allergy & Clinical Immunology, is a leading journal dedicated to advancing the fields of immunology, allergy, and respiratory medicine. With an ISSN of 2092-7355 and an E-ISSN of 2092-7363, this esteemed publication has been a cornerstone for researchers and practitioners since its inception in 2009 and continues to disseminate critical findings through till 2024. The journal is ranked in the Q3 category in Immunology and the Q2 category in Immunology and Allergy as well as Pulmonary and Respiratory Medicine, illustrating its impact in these vital fields. With a solid Scopus ranking in multiple sub-disciplines, the journal not only contributes to the scientific discourse but also promotes innovative research and clinical practices. Although currently operating without an open access model, the journal remains highly regarded for its thorough peer-review process and commitment to academic excellence, making it an essential resource for professionals, researchers, and students passionate about advancing knowledge in allergy, asthma, and immunology.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY is an esteemed publication dedicated to the fields of Immunology and Allergy, published by ESMON PUBLICIDAD S A in collaboration with the Department of Allergy and Clinical Immunology at the University Clinical Navarra, Spain. With its rich history spanning over three decades since its inception in 1991, this journal has gained prominence in the scientific community, holding a commendable Q2 quartile in Allergy and a Q3 quartile in Immunology. Ranked within the top tiers of its categories according to Scopus, it stands at Rank #80/233 in Immunology and Allergy, and Rank #96/236 in Immunology and Microbiology, indicating its influential role in disseminating cutting-edge research and clinical insights. Though primarily print-focused, the journal strives to bridge gaps in knowledge and contribute to the ongoing dialogue among researchers, professionals, and students in the immunological sciences. The JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY is essential for anyone committed to advancing the understanding of allergic and immunological conditions.

Current Treatment Options in Allergy is an esteemed academic journal published by SpringerNature, focusing on a critical area of health science: the evolving landscape of allergy treatments. With an E-ISSN of 2196-3053, this journal aims to provide a comprehensive platform for researchers and practitioners in the fields of Immunology and Allergy and Medicine. It has garnered recognition in the academic community, reflecting its significant contribution with a Q3 ranking in Immunology and Allergy and a Q3 ranking in Medicine as of 2023. The journal is based in Switzerland and encompasses research spanning from 2014 to 2024, ensuring that the latest findings and treatment options are available to professionals and students alike. With a growing focus on open access, it aims to make critical allergy treatment research widely accessible, thus fostering innovation and collaboration in this vital health sector. As the prevalence of allergies continues to rise globally, Current Treatment Options in Allergy plays a crucial role in disseminating important research and treatment strategies to improve patient outcomes.

ALLERGOLOGY INTERNATIONAL is a prestigious, peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Published by the Japanese Society of Allergology, this Open Access journal has been democratizing knowledge since 1996, providing a platform for the latest findings and clinical practices in the management of allergic diseases. Its impressive Q1 ranking in both Immunology and Allergy** and **Medicine (miscellaneous)** categories in 2023 highlights its significance in the global scientific community, with a commendable Scopus ranking of #31 out of 233 in the field of immunology. The journal's focus on innovative research, comprehensive reviews, and case studies ensures that it remains a vital resource for researchers, healthcare professionals, and students alike. Situated in Tokyo, Japan, it continues to bridge gaps in allergy-related health information and foster international collaboration among scholars.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.